PTC Therapeutics To Acquire Agilis Biotherapeutics For $50M Cash and $150M In Common Stock With Potential Future $60M In Milestone Payments, With An Add'l $535M In Regulatory Approval Milestone Payments and $150M In Tiered Commercial Milestones of $150M
Benzinga Newsdesk